Veru Revenue and Competitors
Estimated Revenue & Valuation
- Veru's estimated annual revenue is currently $15.3M per year.
- Veru's estimated revenue per employee is $155,000
Employee Data
- Veru has 99 Employees.
Veru's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman, CEO, and President | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Vice Chairman, Chief Corporate Officer | Reveal Email/Phone |
4 | CFO and CAO | Reveal Email/Phone |
5 | VP Regulatory Affairs | Reveal Email/Phone |
6 | VP Head Medical Affairs | Reveal Email/Phone |
7 | EVP | Reveal Email/Phone |
8 | EVP, GM and Head Infectious Disease Franchise | Reveal Email/Phone |
9 | EVP, General Manager - EMEA, UK, Canada, Latin America, Asia Pacific | Reveal Email/Phone |
10 | Head Quality Assurance | Reveal Email/Phone |
Veru Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Veru?
N/A
Total Funding
99
Number of Employees
$15.3M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Veru News
2022-04-17 - Is Veru Stock a Buy Now?
Veru (NASDAQ: VERU) is a bit of an oddball in biotech. It's developing medicines for breast cancer and treatment-resistant prostate cancer,...
2022-04-13 - Veru Stock Could Hit $36, Says Oppenheimer
Avid stock market watchers will know the biotech space operates according to a different rule set. One session can wipe off a huge chunk of...
2022-04-06 - Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized
Patients in Interim Analysis of Phase ...
Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.8M | 99 | 13% | N/A |
#2 | $34.9M | 99 | 2% | N/A |
#3 | $28.7M | 99 | 24% | N/A |
#4 | $14.4M | 99 | N/A | N/A |
#5 | $14.4M | 99 | N/A | N/A |